PTPatrick J. Tu

Patrick J. Tu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrick J. Tu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical controversies in the management of candidemia in adults and children

    by David B Cluck, Bryan P White, Sarah A Hilzendager, Jonathan H Ryder, Patrick J Tu, Amanda Z McPherson, Daniel J Rogers, Daniel B Chastain

    Purpose: Candidemia remains associated with substantial morbidity and mortality despite advances in antifungal therapy, yet multiple aspects of management remain controversial. This review synthesizes emerging evidence to address unresolved clinical dilemmas in candidemia management. Summary: This publication reviews data on optimized antifungal dosing, rapid diagnostic tests (RDTs), antifungal susceptibility testing (AFST), echinocandin-to-azole transition, treatment duration, ophthalmologic screening, echocardiographic evaluation, Candida endocarditis, the place in therapy of rezafungin, antifungal resistance, and dosing considerations in children. Substantial pharmacokinetic variability in critically ill and obese patients supports individualized dosing strategies to reduce underexposure. Echinocandin-to-azole transition after 3 to 5 days appears safe in clinically stable patients with bloodstream sterilization and predicted or confirmed azole susceptibility. Although the standard 14-day duration remains a guideline-supported recommendation, emerging evidence suggesting shorter durations may be feasible in carefully selected patients with truly uncomplicated candidemia. Risk-based approaches to ophthalmologic screening and echocardiography may improve diagnostic stewardship while reducing unnecessary testing. Echinocandins appear at least as effective and safer than amphotericin B for Candida endocarditis. Rezafungin offers a practical once-weekly alternative for select patients requiring prolonged intravenous therapy, although evidence for deep-seated infection remains limited. Increasing resistance among non-albicans Candida species, particularly C. parapsilosis, C. glabrata, and C. auris further reinforces the importance of AFST and ongoing surveillance. Conclusion: Optimal candidemia management increasingly depends on individualized antifungal strategies, integration of RDTs and AFST, earlier species-directed therapy transitions, and selective evaluation for metastatic complications. Future studies are needed to better define uncomplicated candidemia, optimize treatment duration, and address evolving antifungal resistance.

  • Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review

    by Jessica E. Burchette, Kelly Covert, Patrick Tu, Bryan P. White, Daniel B. Chastain, David B. Cluck

    Objective: To review the evidence and discuss use of pivmecillinam in uncomplicated acute cystitis. Data sources: A literature search was conducted utilizing PubMed (from 2000 through August 2024) and ClinicalTrials.gov. Medical Subject Headings (MeSH) terms, such as mecillinam or pivmecillinam and urinary tract infections, were utilized. Additional references were identified by reviewing literature citations. Study selection and data extraction: Articles were limited to English language publications evaluating the efficacy or safety of pivmecillinam for urinary tract infections (UTIs) in adult populations. Data synthesis: Data from 6 randomized controlled trials support pivmecillinam for acute uncomplicated cystitis at doses of 200 to 400 mg 3 times daily for 3 to 7 days, with more consistent clinical and bacteriologic cure observed with 400 mg doses and longer therapy durations. Clinical evaluation of 400 mg 2 to 3 times daily is available with use more common in non–US Food and Drug Administration (FDA)-approved populations, such as men, pregnancy, and multidrug resistant infections. There are limited data supporting pivmecillinam for pyelonephritis; routine use is cautioned until further clinical data are available. Relevance to patient care and clinical practice in comparison with existing drugs: As resistance to first-line antimicrobials rises, the need for safe and effective treatment options remains high. Pivmecillinam represents a new therapeutic option available in the United States for outpatient management of uncomplicated acute cystitis. Conclusion: Pivmecillinam could be a key agent for uncomplicated acute cystitis. Utilization will likely be cost driven, but the promise of low resistance encourages the place in therapy when other agents are not susceptible to infecting uropathogens.


  • Evaluation of Sequential Oral Versus Intravenous Antibiotic Treatment of Enterococcus faecalis Bloodstream Infections

    by Carly Loudermilk, Joshua Eudy, Stephanie Albrecht, Cara N. Slaton, Stefanie Stramel, Patrick Tu, Benjamin Albrecht, Sarah B. Green, Jeannette L. Bouchard, Alison I. Orvin, et al.

    Background: Intravenous (IV) antibiotics have historically been considered standard of care for treatment of bloodstream infections (BSIs). Recent literature has shown sequential oral (PO) therapy to be noninferior to IV antibiotics for certain pathogens and disease states. However, a gap exists in the literature for BSI caused by Enterococcus faecalis. Objective: To compare outcomes of definitive sequential PO therapy to definitive IV therapy in patients with E faecalis BSI. Methods: Multicenter, retrospective, matched cohort study of adult patients with at least one blood culture positive for E faecalis from January 2017 to November 2022. Patients with polymicrobial BSI, concomitant infections requiring prolonged IV antibiotic therapy, those who did not receive antibiotic therapy, and those who died within 72 hours of index culture were excluded. Subjects were matched based on source of infection in a 2:1 (IV:PO) ratio. The primary outcome was a composite of all-cause mortality and treatment failure. Secondary outcomes included hospital length of stay (LOS), antibiotic duration, and 30-day readmission rate. Results: Of the 186 patients who met criteria for inclusion, there was no statistically significant difference in the primary composite outcome for PO compared to IV therapy (14.5% vs 21.8%; OR 0.53 [0.23-1.25]) or 30-day readmission (17.5% vs 29%; OR 0.53 [0.25-1.13]). Hospital LOS was significantly longer in patients receiving IV-only therapy (6 days vs 14 days; P < 0.001). Conclusion and Relevance: Sequential oral therapy for E faecalis BSI had similar outcomes compared to IV-only treatment and may be considered in eligible patients.


  • Open Access

    Managing Modern Antiretroviral Therapy in the Intensive Care Unit: Overcoming Challenges for Critically Ill People With Human Immunodeficiency Virus

    by Daniel B Chastain, Patrick J Tu, Marisa Brizzi, Chelsea A Keedy, Aubrey N Baker, Brittany T Jackson, Amber F Ladak, Leslie A Hamilton, Nicholas R Sells, Andrés F Henao-Martínez, et al.

    People with human immunodeficiency virus (HIV) have a 50% excess risk for intensive care unit (ICU) admission, often for non-HIV-related conditions. Despite this, clear guidance for managing antiretroviral therapy (ART) in this setting is lacking. Selecting appropriate ART in the ICU is complex due to drug interactions, absorption issues, and dosing adjustments. Continuing ART in the ICU can be challenging due to organ dysfunction, drug interactions, and formulary limitations. However, with careful consideration, continuation is often feasible through dose adjustments or alternative administration methods. Temporary discontinuation of ART may be beneficial depending on the clinical scenario. Clinicians should actively seek resources and support to mitigate adverse events and drug interactions in critically ill people with HIV. Navigating challenges in the ICU can optimize ART and improve care and outcomes for critically ill people with HIV. This review aims to identify strategies for addressing the challenges associated with the use of modern ART in the ICU.


  • Open Access

    The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel β-lactam antibiotics in the southeastern United States

    by Y. Vivian Tsai, P. Brandon Bookstaver, Joseph Kohn, Julie Ann Justo, Darrell Childress, Stefanie Stramel, Douglas Slain, Patrick Tu, Mary Joyce B. Wingler, Bruce M. Jones, et al.

    Objective: To evaluate temporal trends in the prevalence of gram-negative bacteria (GNB) with difficult-to-treat resistance (DTR) in the southeastern United States. Secondary objective was to examine the use of novel β-lactams for GNB with DTR by both antimicrobial use (AU) and a novel metric of adjusted AU by microbiological burden (am-AU).Design: Retrospective, multicenter, cohort.Setting: Ten hospitals in the southeastern United States.Methods: GNB with DTR including Enterobacterales,Pseudomonas aeruginosa, andAcinetobacterspp. from 2015 to 2020 were tracked at each institution. Cumulative AU of novel β-lactams including ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilastatin/relebactam, and cefiderocol in days of therapy (DOT) per 1,000 patient-days was calculated. Linear regression was utilized to examine temporal trends in the prevalence of GNB with DTR and cumulative AU of novel β-lactams.Results: The overall prevalence of GNB with DTR was 0.85% (1,223/143,638) with numerical increase from 0.77% to 1.00% between 2015 and 2020 (P= .06). There was a statistically significant increase in DTR Enterobacterales (0.11% to 0.28%,P= .023) and DTRAcinetobacterspp. (4.2% to 18.8%,P= .002). Cumulative AU of novel β-lactams was 1.91 ± 1.95 DOT per 1,000 patient-days. When comparing cumulative mean AU and am-AU, there was an increase from 1.91 to 2.36 DOT/1,000 patient-days, with more than half of the hospitals shifting in ranking after adjustment for microbiological burden.Conclusions: The overall prevalence of GNB with DTR and the use of novel β-lactams remain low. However, the uptrend in the use of novel β-lactams after adjusting for microbiological burden suggests a higher utilization relative to the prevalence of GNB with DTR.


  • Candidemia in Adult Patients in the ICU: A Reappraisal of Susceptibility Testing and Antifungal Therapy

    by Daniel B. Chastain, Bryan P. White, Patrick J. Tu, Sophea Chan, Brittany T. Jackson, Kara A. Kubbs, Aiman Bandali, Steven McDougal, Andrés F. Henao-Martínez, David B. Cluck

    Objective: To provide updates on the epidemiology and recommendations for management of candidemia in patients with critical illness. Data Sources: A literature search using the PubMed database (inception to March 2023) was conducted using the search terms “invasive candidiasis,” “candidemia,” “critically ill,” “azoles,” “echinocandin,” “antifungal agents,” “rapid diagnostics,” “antifungal susceptibility testing,” “therapeutic drug monitoring,” “antifungal dosing,” “persistent candidemia,” and “Candida biofilm.” Study Selection/Data Extraction: Clinical data were limited to those published in the English language. Ongoing trials were identified through ClinicalTrials.gov. Data Synthesis: A total of 109 articles were reviewed including 25 pharmacokinetic/pharmacodynamic studies and 30 studies including patient data, 13 of which were randomized controlled clinical trials. The remaining 54 articles included fungal surveillance data, in vitro studies, review articles, and survey data. The current 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Management of Candidiasis provides recommendations for selecting empiric and definitive antifungal therapies for candidemia, but data are limited regarding optimized dosing strategies in critically ill patients with dynamic pharmacokinetic changes or persistent candidemia complicated. Relevance to Patient Care and Clinical Practice: Outcomes due to candidemia remain poor despite improved diagnostic platforms, antifungal susceptibility testing, and antifungal therapy selection for candidemia in critically ill patients. Earlier detection and identification of the species causing candidemia combined with recognition of patient-specific factors leading to dosing discrepancies are crucial to improving outcomes in critically ill patients with candidemia. Conclusions: Treatment of candidemia in critically ill patients must account for the incidence of non-albicans Candida species and trends in antifungal resistance as well as overcome the complex pathophysiologic changes to avoid suboptimal antifungal exposure.


  • Therapeutic Options for Adult Patients With Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Narrative Review

    by Daniel B. Chastain, Kelly L. Covert, Patrick J. Tu, Steven McDougal, Bryan P. White, David Cluck

    Objective: To compare the efficacy of antimicrobial therapies used in the management of persistent methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Data Sources: A literature search using the PubMed database (inception to December 2022) was conducted using the search terms “ Staphylococcus aureus bacteremia,” “methicillin-susceptible Staphylococcus aureus bacteremia,” “persistent methicillin-susceptible Staphylococcus aureus bacteremia,” and “refractory methicillin-susceptible Staphylococcus aureus bacteremia .” In addition, therapeutic agents which could be used as treatment for MSSA including “nafcillin,” “oxacillin,” “cefazolin,” “ceftaroline,” “gentamicin,” “rifampin,” and “daptomycin” were also combined with the aforementioned search terms to capture data using these agents. Study Selection/Data Extraction: Clinical data were limited to those published in the English language. Articles and abstracts were considered for inclusion in addition to ongoing trials identified through ClinicalTrials.gov. Data Synthesis: A total of 78 articles were reviewed including 17 in vitro or animal model studies and 39 studies including patient data. The remaining 22 articles included guidelines, review articles, and editorials. Recent data evaluating use of dual β-lactam regimens for persistent MSSA bacteremia were limited to 8 case reports or case series. Relevance to Patient Care and Clinical Practice: At present, there is little guidance on how to best manage patients with persistent MSSA bacteremia. This narrative review collates the available data to assist clinicians in selecting the best possible antimicrobial regimen when facing this clinical conundrum. Conclusions: Modification of antimicrobial therapy, in conjunction with source control and infectious diseases consultation, may all be necessary to sterilize blood cultures in patients with persistent MSSA bacteremia.